Literature DB >> 18304600

HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein.

David R Morcock1, James A Thomas, Raymond C Sowder, Louis E Henderson, Bruce J Crise, Robert J Gorelick.   

Abstract

Selective inactivation of critical cysteine residues in human immunodeficiency virus type one (HIV-1) was observed after treatment with 4-vinylpyridine (4-VP), with and without the membrane-permeable metal chelator N,N,N',N'-tetrakis(2-pyridylmethyl)-ethylenediamine (TPEN). Chromatographic analysis showed that cysteines contained within nucleocapsid zinc fingers, in the context of whole virus or purified protein, were essentially unreactive, but became reactive when a chelator was included. Virus treated with 4-VP showed only a modest decrease in infectivity; after TPEN addition, nearly complete inactivation of HIV-1 occurred. Similarly, quantitation of viral DNA products from 4-VP-treated virus infections showed no significant effects on reverse transcription, but did show a 14-fold reduction in proviruses; when TPEN was added, a 10(5)-fold decrease in late reverse transcription products was observed and no proviruses were detected. Since 4-VP effectiveness was greatly enhanced by TPEN, this strongly suggests that modification of nucleocapsid zinc fingers is necessary and sufficient for HIV-1 inactivation by sulfhydryl reagents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18304600      PMCID: PMC2553892          DOI: 10.1016/j.virol.2008.01.045

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  69 in total

1.  Human immunodeficiency virus type 1 nucleocapsid protein specifically stimulates Mg2+-dependent DNA integration in vitro.

Authors:  S Carteau; S C Batson; L Poljak; J F Mouscadet; H de Rocquigny; J L Darlix; B P Roques; E Käs; C Auclair
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Potential metal-binding domains in nucleic acid binding proteins.

Authors:  J M Berg
Journal:  Science       Date:  1986-04-25       Impact factor: 47.728

3.  Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA.

Authors:  R J Gorelick; S M Nigida; J W Bess; L O Arthur; L E Henderson; A Rein
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

4.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  Inactivation of murine leukemia virus by compounds that react with the zinc finger in the viral nucleocapsid protein.

Authors:  A Rein; D E Ott; J Mirro; L O Arthur; W Rice; L E Henderson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element.

Authors:  R N De Guzman; Z R Wu; C C Stalling; L Pappalardo; P N Borer; M F Summers
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

7.  Characterization of intermediates in the oxidation of zinc fingers in human immunodeficiency virus type 1 nucleocapsid protein P7.

Authors:  Y Hathout; D Fabris; M S Han; R C Sowder; L E Henderson; C Fenselau
Journal:  Drug Metab Dispos       Date:  1996-12       Impact factor: 3.922

8.  Tightly bound zinc in human immunodeficiency virus type 1, human T-cell leukemia virus type I, and other retroviruses.

Authors:  J W Bess; P J Powell; H J Issaq; L J Schumack; M K Grimes; L E Henderson; L O Arthur
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

9.  Point mutants of Moloney murine leukemia virus that fail to package viral RNA: evidence for specific RNA recognition by a "zinc finger-like" protein sequence.

Authors:  R J Gorelick; L E Henderson; J P Hanser; A Rein
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

10.  Human immunodeficiency virus type 1 nucleocapsid protein reduces reverse transcriptase pausing at a secondary structure near the murine leukemia virus polypurine tract.

Authors:  W Wu; L E Henderson; T D Copeland; R J Gorelick; W J Bosche; A Rein; J G Levin
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more
  18 in total

Review 1.  Novel approaches to inhibiting HIV-1 replication.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Antiviral Res       Date:  2009-09-24       Impact factor: 5.970

Review 2.  HIV type 1 Gag as a target for antiviral therapy.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-21       Impact factor: 2.205

3.  Relative expression levels of the HLA class-I proteins in normal and HIV-infected cells.

Authors:  Richard Apps; Zhaojing Meng; Gregory Q Del Prete; Jeffrey D Lifson; Ming Zhou; Mary Carrington
Journal:  J Immunol       Date:  2015-03-09       Impact factor: 5.422

4.  Aromatic residue mutations reveal direct correlation between HIV-1 nucleocapsid protein's nucleic acid chaperone activity and retroviral replication.

Authors:  Hao Wu; Mithun Mitra; Micah J McCauley; James A Thomas; Ioulia Rouzina; Karin Musier-Forsyth; Mark C Williams; Robert J Gorelick
Journal:  Virus Res       Date:  2012-07-16       Impact factor: 3.303

5.  Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies.

Authors:  Gregory Q Del Prete; Matthew Scarlotta; Laura Newman; Carolyn Reid; Laura M Parodi; James D Roser; Kelli Oswald; Preston A Marx; Christopher J Miller; Ronald C Desrosiers; Dan H Barouch; Ranajit Pal; Michael Piatak; Elena Chertova; Luis D Giavedoni; David H O'Connor; Jeffrey D Lifson; Brandon F Keele
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

6.  Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapy.

Authors:  Adrienne E Swanstrom; Taina T Immonen; Kelli Oswald; Cathi Pyle; James A Thomas; William J Bosche; Lorna Silipino; Michael Hull; Laura Newman; Vicky Coalter; Adam Wiles; Rodney Wiles; Jacob Kiser; David R Morcock; Rebecca Shoemaker; Randy Fast; Matthew W Breed; Joshua Kramer; Duncan Donohue; Tyler Malys; Christine M Fennessey; Charles M Trubey; Claire Deleage; Jacob D Estes; Jeffrey D Lifson; Brandon F Keele; Gregory Q Del Prete
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

7.  Distinct nucleic acid interaction properties of HIV-1 nucleocapsid protein precursor NCp15 explain reduced viral infectivity.

Authors:  Wei Wang; Nada Naiyer; Mithun Mitra; Jialin Li; Mark C Williams; Ioulia Rouzina; Robert J Gorelick; Zhengrong Wu; Karin Musier-Forsyth
Journal:  Nucleic Acids Res       Date:  2014-05-09       Impact factor: 16.971

8.  Molecularly tagged simian immunodeficiency virus SIVmac239 synthetic swarm for tracking independent infection events.

Authors:  Gregory Q Del Prete; Haesun Park; Christine M Fennessey; Carolyn Reid; Leslie Lipkey; Laura Newman; Kelli Oswald; Christoph Kahl; Michael Piatak; Octavio A Quiñones; W Gregory Alvord; Jeremy Smedley; Jacob D Estes; Jeffrey D Lifson; Louis J Picker; Brandon F Keele
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

9.  Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques.

Authors:  Gregory Q Del Prete; Jeremy Smedley; Rhonda Macallister; Gregg S Jones; Bei Li; Jillian Hattersley; Jim Zheng; Michael Piatak; Brandon F Keele; Joseph Hesselgesser; Romas Geleziunas; Jeffrey D Lifson
Journal:  AIDS Res Hum Retroviruses       Date:  2015-09-09       Impact factor: 2.205

10.  Factors that determine the efficiency of HIV-1 strand transfer initiated at a specific site.

Authors:  Sean T Rigby; Keith P Van Nostrand; April E Rose; Robert J Gorelick; David H Mathews; Robert A Bambara
Journal:  J Mol Biol       Date:  2009-10-21       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.